[go: up one dir, main page]

FR2892937B1 - Forme pharmaceutique orale microparticulaire anti-mesusage - Google Patents

Forme pharmaceutique orale microparticulaire anti-mesusage

Info

Publication number
FR2892937B1
FR2892937B1 FR0553437A FR0553437A FR2892937B1 FR 2892937 B1 FR2892937 B1 FR 2892937B1 FR 0553437 A FR0553437 A FR 0553437A FR 0553437 A FR0553437 A FR 0553437A FR 2892937 B1 FR2892937 B1 FR 2892937B1
Authority
FR
France
Prior art keywords
microparticular
measuring
oral pharmaceutical
pharmaceutical form
form anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0553437A
Other languages
English (en)
Other versions
FR2892937A1 (fr
Inventor
Florence Guimberteau
Frederic Dargelas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Ireland Ltd
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0553437A priority Critical patent/FR2892937B1/fr
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Priority to JP2008539368A priority patent/JP5537030B2/ja
Priority to EP06763289A priority patent/EP1945230A1/fr
Priority to AU2006311116A priority patent/AU2006311116C1/en
Priority to MX2008006042A priority patent/MX2008006042A/es
Priority to BRPI0618502-9A priority patent/BRPI0618502A2/pt
Priority to KR1020147014471A priority patent/KR20140090222A/ko
Priority to CNA2006800422365A priority patent/CN101304752A/zh
Priority to PCT/EP2006/062627 priority patent/WO2007054378A1/fr
Priority to CA002627058A priority patent/CA2627058A1/fr
Priority to KR1020087013970A priority patent/KR101425196B1/ko
Priority to US11/439,432 priority patent/US8652529B2/en
Publication of FR2892937A1 publication Critical patent/FR2892937A1/fr
Priority to IL190749A priority patent/IL190749A/en
Priority to ZA200803140A priority patent/ZA200803140B/xx
Priority to US12/638,739 priority patent/US8445023B2/en
Application granted granted Critical
Publication of FR2892937B1 publication Critical patent/FR2892937B1/fr
Priority to US14/081,038 priority patent/US20140072644A1/en
Priority to IL233925A priority patent/IL233925A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0553437A 2005-11-10 2005-11-10 Forme pharmaceutique orale microparticulaire anti-mesusage Active FR2892937B1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR0553437A FR2892937B1 (fr) 2005-11-10 2005-11-10 Forme pharmaceutique orale microparticulaire anti-mesusage
CA002627058A CA2627058A1 (fr) 2005-11-10 2006-05-24 Forme pharmaceutique orale microparticulaire anti-mesusage
AU2006311116A AU2006311116C1 (en) 2005-11-10 2006-05-24 Anti-misuse microparticulate oral pharmaceutical form
MX2008006042A MX2008006042A (es) 2005-11-10 2006-05-24 Forma farmaceutica oral de microparticulado anti-mal uso.
BRPI0618502-9A BRPI0618502A2 (pt) 2005-11-10 2006-05-24 forma farmacêutica oral de micropartìculas contra mau uso
KR1020147014471A KR20140090222A (ko) 2005-11-10 2006-05-24 오용 방지 극미립자 경구 약학 제형
CNA2006800422365A CN101304752A (zh) 2005-11-10 2006-05-24 防滥用的微粒口服药物形式
PCT/EP2006/062627 WO2007054378A1 (fr) 2005-11-10 2006-05-24 Forme pharmaceutique orale microparticulaire anti-mesusage
JP2008539368A JP5537030B2 (ja) 2005-11-10 2006-05-24 誤用防止微粒子経口医薬形態
KR1020087013970A KR101425196B1 (ko) 2005-11-10 2006-05-24 오용 방지 극미립자 경구 약학 제형
US11/439,432 US8652529B2 (en) 2005-11-10 2006-05-24 Anti-misuse microparticulate oral pharmaceutical form
EP06763289A EP1945230A1 (fr) 2005-11-10 2006-05-24 Forme pharmaceutique orale microparticulaire anti-mesusage
IL190749A IL190749A (en) 2005-11-10 2008-04-09 Pharmaceutical dose for oral administration in the form of tiny particles to prevent misuse
ZA200803140A ZA200803140B (en) 2005-11-10 2008-04-09 Anti-misuse microparticulate oral pharmaceutical form
US12/638,739 US8445023B2 (en) 2005-11-10 2009-12-15 Anti-misuse microparticulate oral pharmaceutical form
US14/081,038 US20140072644A1 (en) 2005-11-10 2013-11-15 Anti-misuse microparticulate oral pharmaceutical form
IL233925A IL233925A (en) 2005-11-10 2014-08-03 Pharmaceutical dose for oral administration in the form of tiny particles to prevent misuse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0553437A FR2892937B1 (fr) 2005-11-10 2005-11-10 Forme pharmaceutique orale microparticulaire anti-mesusage

Publications (2)

Publication Number Publication Date
FR2892937A1 FR2892937A1 (fr) 2007-05-11
FR2892937B1 true FR2892937B1 (fr) 2013-04-05

Family

ID=36930690

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0553437A Active FR2892937B1 (fr) 2005-11-10 2005-11-10 Forme pharmaceutique orale microparticulaire anti-mesusage

Country Status (12)

Country Link
EP (1) EP1945230A1 (fr)
JP (1) JP5537030B2 (fr)
KR (2) KR20140090222A (fr)
CN (1) CN101304752A (fr)
AU (1) AU2006311116C1 (fr)
BR (1) BRPI0618502A2 (fr)
CA (1) CA2627058A1 (fr)
FR (1) FR2892937B1 (fr)
IL (2) IL190749A (fr)
MX (1) MX2008006042A (fr)
WO (1) WO2007054378A1 (fr)
ZA (1) ZA200803140B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
CN102573806B (zh) 2009-07-22 2015-02-25 格吕伦塔尔有限公司 用于对氧化敏感的阿片类物质的抗破坏剂型
FR2949062B1 (fr) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
FR2962331B1 (fr) * 2010-07-06 2020-04-24 Ethypharm Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
CA2808219C (fr) 2010-09-02 2019-05-14 Gruenenthal Gmbh Forme pharmaceutique inviolable comportant un sel inorganique
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
AU2012219322A1 (en) * 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
MX357551B (es) * 2011-03-23 2018-07-13 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
ES2655900T3 (es) * 2011-07-29 2018-02-22 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
WO2013017242A1 (fr) 2011-07-29 2013-02-07 Grünenthal GmbH Comprimé anti-manipulation permettant une libération immédiate de médicament
FR2983409B1 (fr) * 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
FR2999426B1 (fr) 2012-12-13 2015-01-02 Flamel Tech Sa Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage.
BR112015017451B1 (pt) 2013-02-05 2023-01-10 Purdue Pharma L.P. Formulações farmacêuticas resistentes à violação
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
CA2913209A1 (fr) 2013-05-29 2014-12-04 Grunenthal Gmbh Forme dosifiee inviolable a profil de liberation bimodale
FR3007651A1 (fr) * 2013-06-27 2015-01-02 Assist Publ Hopitaux De Paris Composition pharmaceutique sous forme de granules pour le traitement de desordres metaboliques chez l'enfant
CA2917136C (fr) 2013-07-12 2022-05-31 Grunenthal Gmbh Forme posologique inviolable contenant un polymere d'ethylene-acetate de vinyle
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015173195A1 (fr) 2014-05-12 2015-11-19 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
WO2016064873A1 (fr) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
CA3085348A1 (fr) 2017-12-20 2019-06-27 Purdue Pharma L.P. Formes galeniques de sulfate de morphine dissuasives d'abus
CN112402386B (zh) * 2020-12-04 2022-06-28 江苏恩华药业股份有限公司 一种防滥用的阿片类药物口服缓释片及其制备方法
CN112451493B (zh) * 2020-12-04 2022-06-28 江苏恩华药业股份有限公司 一种防滥用的羟考酮口服缓释片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693270B2 (ja) * 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
EP1204406A2 (fr) * 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Preparation d'opioide a liberation continue
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
KR20040025741A (ko) * 2001-08-06 2004-03-25 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
AU2003220551A1 (en) * 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
CA2491572C (fr) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
WO2004026262A2 (fr) * 2002-09-23 2004-04-01 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
FR2878161B1 (fr) * 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
FR2878158B1 (fr) * 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
WO2006133733A1 (fr) * 2005-06-13 2006-12-21 Flamel Technologies Forme posologique orale comportant un systeme anti-abus

Also Published As

Publication number Publication date
IL190749A (en) 2015-07-30
KR101425196B1 (ko) 2014-08-12
CN101304752A (zh) 2008-11-12
JP2009537456A (ja) 2009-10-29
AU2006311116C1 (en) 2013-10-24
AU2006311116B2 (en) 2013-01-31
IL190749A0 (en) 2008-12-29
WO2007054378A1 (fr) 2007-05-18
KR20140090222A (ko) 2014-07-16
KR20080064905A (ko) 2008-07-09
ZA200803140B (en) 2009-08-26
IL233925A (en) 2017-12-31
AU2006311116A1 (en) 2007-05-18
FR2892937A1 (fr) 2007-05-11
JP5537030B2 (ja) 2014-07-02
IL233925A0 (en) 2014-09-30
CA2627058A1 (fr) 2007-05-18
EP1945230A1 (fr) 2008-07-23
BRPI0618502A2 (pt) 2011-09-06
MX2008006042A (es) 2008-10-01

Similar Documents

Publication Publication Date Title
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
NO20075628L (no) Farmasøytiske formuleringer
BRPI0511900A (pt) composições farmacêuticas
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
RU2398586C3 (ru) Фармацевтическая композиция
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0714539A2 (pt) "formas farmacêuticas"
DK1957073T3 (da) Lægemiddel
FR2901478B1 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
EP1871347A4 (fr) Preparation pharmaceutique
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
ATE453384T1 (de) Neue dosierformulierung
DK1587478T3 (da) Farmaceutisk sammensætning
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
EP1937255A4 (fr) Composition pharmaceutique
EP1862184A4 (fr) Composition pharmaceutique
EP1937414A4 (fr) Forme pharmaceutique pour muqueuses orales
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
DK1757293T3 (da) Bh4-responsiv hyperphenylalaninæmi-medikamenter
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
NO20034952D0 (no) Farmasöytiske forbindelser
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
EP1747205A4 (fr) Compositions pharmaceutiques

Legal Events

Date Code Title Description
LIMR Limitation of claims

Effective date: 20130626

PLFP Fee payment

Year of fee payment: 11

TP Transmission of property

Owner name: FLAMEL IRELAND LIMITED, IE

Effective date: 20151119

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13